![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Prada Patricia O
Publisher: Informa Healthcare
ISSN: 1354-3784
Source: Expert Opinion on Investigational Drugs, Vol.22, Iss.6, 2013-09, pp. : 751-763
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Novel Tyrosine Kinase Inhibitors in the Treatment of Cancer
Current Drug Targets, Vol. 10, Iss. 6, 2009-06 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Novel FLT3 tyrosine kinase inhibitors
Expert Opinion on Investigational Drugs, Vol. 12, Iss. 12, 2003-12 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Protein tyrosine kinase inhibitors in cancer treatment
By Traxler P.M.
Expert Opinion on Therapeutic Patents, Vol. 7, Iss. 6, 1997-06 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Tyrosine kinase inhibitors in cancer treatment (Part II)
By Traxler P.
Expert Opinion on Therapeutic Patents, Vol. 8, Iss. 12, 1998-12 ,pp. :